Royalty Pharma plc (NASDAQ:RPRX - Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $34.63 and last traded at $34.41, with a volume of 704107 shares changing hands. The stock had previously closed at $34.05.
Analyst Ratings Changes
Several analysts have issued reports on the company. Morgan Stanley assumed coverage on Royalty Pharma in a research report on Friday, May 16th. They set an "overweight" rating and a $51.00 target price on the stock. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. Finally, Wall Street Zen cut Royalty Pharma from a "buy" rating to a "hold" rating in a research report on Tuesday, May 20th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $47.33.
Read Our Latest Stock Report on RPRX
Royalty Pharma Price Performance
The stock has a market cap of $19.59 billion, a price-to-earnings ratio of 24.03, a PEG ratio of 2.31 and a beta of 0.48. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The stock has a 50-day moving average price of $32.82 and a two-hundred day moving average price of $30.98.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.99 by $0.07. The firm had revenue of $839.00 million during the quarter, compared to analyst estimates of $724.69 million. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, equities research analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.
Royalty Pharma Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.53%. The ex-dividend date of this dividend was Friday, May 16th. Royalty Pharma's payout ratio is currently 47.57%.
Institutional Trading of Royalty Pharma
A number of institutional investors and hedge funds have recently added to or reduced their stakes in RPRX. Allworth Financial LP lifted its position in Royalty Pharma by 417.6% during the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 877 shares during the period. Louisbourg Investments Inc. acquired a new stake in Royalty Pharma during the 1st quarter worth about $28,000. MassMutual Private Wealth & Trust FSB lifted its position in Royalty Pharma by 76.4% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 414 shares during the period. Riverview Trust Co lifted its position in Royalty Pharma by 3,953.3% during the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 1,186 shares during the period. Finally, Summit Securities Group LLC acquired a new stake in Royalty Pharma during the 1st quarter worth about $36,000. Institutional investors and hedge funds own 54.35% of the company's stock.
About Royalty Pharma
(
Get Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
See Also
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
